m. Shkreli had a specialty to redeem patents of cheap drugs and then massively increase the price. It must pay nearly $ 65 million.
Le Monde with AFP
Nicknamed a time “The most hated man of the United States”, he had attracted the wrath of the American political world after leaving the price of Daraprim, a drug against toxoplasmosis and malaria, of … 5,400%.
The provocative contractor in Pharmacy Martin Shkreli, 38, was found guilty of monopoly and sentenced, Friday, January 14, to reverse the profits he had withdrawn from his anti-competitive practices, nearly $ 65 million ( nearly 57 million euros). Imprisoned for another case, the man has also been banned for life from the pharmaceutical sector, decided by Judge Denise Cote.
m. Shkreli had a specialty to redeem patents of cheap drugs and then massively increase the price. Daraprim has thus spent overnight from 13.50 to 750 dollars (from 12.1 to 673 euros) in 2015. The American Competition Authority and the Prosecutors of Seven States had filed a complaint in January 2020 against the entrepreneur and society he had founded.
released in November 2022
Centered Turing Originally and since renown Vyype, the latter had committed in December not to try to once again block competition on this product and to pay up to $ 40 million to a fund. Compensation for paying prosecutions.
The agreement did not engage its founder, who officially sold the reins of the company at the end of 2015. The trial of Martin Shkreli took place over seven days in December. Already sentenced in 2018 to seven years in prison for stock market fraud, he is currently serving his sentence in a pennylvania’s penitentiary establishment and theoretically be released in November 2022.
m. Shkreli not only increased the price of Daraprim, but he also organized to prevent the arrival of competitors on the market as long as possible, said the judge. Vyype has on one part prevented generic drug manufacturers from accessing a sufficient amount of Daraprim to conduct the necessary tests, has it detailed. By knotting exclusivity agreements, the company also blocked access to two essential ingredients to the manufacture of the product.
m. Shkreli can be held responsible for this strategy since, even after waived its titles of Director General and President of the Board of Directors, he continued to exercise a certain control over the management of the company as a majority shareholder , including from prison, “said the judge.